|
|
||||||||
Departments of 1Pathology, 2Cardiology, 3Clinical Chemistry, 4Physiology, and 5Gynecology, Vrije Universiteit Medical Center, and 6Institute for Cardiovascular Research, Vrije Universiteit, 1007 MB Amsterdam, The Netherlands; 7Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California 92037; and 8Sanquin Reseach, Central Laboratory of The Netherlands Red Cross Blood Transfusion Service, Department of Immunopathology, 1006 AN Amsterdam, The Netherlands
Submitted 8 October 2002 ; accepted in final form 3 June 2003
Type II secretory phospholipase A2 (sPLA2) is a cardiovascular risk factor. We recently found depositions of sPLA2 in the necrotic center of infarcted human myocardium and normally appearing cardiomyocytes adjacent to the border zone. The consequences of binding of sPLA2 to ischemic cardiomyocytes are not known. To explore a potential effect of sPLA2 on ischemic cardiomyocytes at a cellular level we used an in vitro model. The cardiomyocyte cell line H9c2 or adult cardiomyocytes were isolated from rabbits that were incubated with sPLA2 in the presence of metabolic inhibitors to mimic ischemia-reperfusion conditions. Cell viability was established with the use of annexin V and propidium iodide or 7-aminoactinomycin D. Metabolic inhibition induced an increase of the number of flip-flopped cells, including a population that did not stain with propidium iodide and that was caspase-3 negative. sPLA2 bound to the flip-flopped cells, including those negative for caspase-3. sPLA2 binding induced cell death in these latter cells. In addition, sPLA2 potentiated the binding of C-reactive protein (CRP) to these cells. We conclude that by binding to flip-flopped cardiomyocytes, including those that are caspase-3 negative and presumably reversibly injured, sPLA2 may induce cell death and tag these cells with CRP.
myocardial infarction; inflammation
This article has been cited by other articles:
![]() |
R. Saeedi, V. V. Saran, S. S. Y. Wu, E. S. Kume, K. Paulson, A. P. K. Chan, H. L. Parsons, R. B. Wambolt, J. R. B. Dyck, R. W. Brownsey, et al. AMP-activated protein kinase influences metabolic remodeling in H9c2 cells hypertrophied by arginine vasopressin Am J Physiol Heart Circ Physiol, June 1, 2009; 296(6): H1822 - H1832. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Meischl, H. P. Buermans, T. Hazes, M. J. Zuidwijk, R. J. P. Musters, C. Boer, A. van Lingen, W. S. Simonides, M. A. Blankenstein, C. Dupuy, et al. H9c2 cardiomyoblasts produce thyroid hormone Am J Physiol Cell Physiol, May 1, 2008; 294(5): C1227 - C1233. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. A. J. Krijnen, S. A. G. M. Cillessen, R. Manoe, A. Muller, C. A. Visser, C. J. L. M. Meijer, R. J. P. Musters, C. E. Hack, L. A. Aarden, and H. W. M. Niessen Clusterin: a protective mediator for ischemic cardiomyocytes? Am J Physiol Heart Circ Physiol, November 1, 2005; 289(5): H2193 - H2202. [Abstract] [Full Text] [PDF] |
||||
![]() |
P A J Krijnen, C Ciurana, T Cramer, T Hazes, C J L M Meijer, C A Visser, H W M Niessen, and C E Hack IgM colocalises with complement and C reactive protein in infarcted human myocardium J. Clin. Pathol., April 1, 2005; 58(4): 382 - 388. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Boekholdt, T. T. Keller, N. J. Wareham, R. Luben, S. A. Bingham, N. E. Day, M. S. Sandhu, J. W. Jukema, J. J.P. Kastelein, C. E. Hack, et al. Serum Levels of Type II Secretory Phospholipase A2 and the Risk of Future Coronary Artery Disease in Apparently Healthy Men and Women: The EPIC-Norfolk Prospective Population Study Arterioscler Thromb Vasc Biol, April 1, 2005; 25(4): 839 - 846. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |